Prepping for Trump & Alzheimer’s ethics: a BioCentury podcast

Also on BioCentury This Week: AZ’s China trouble and the myths that shape perceptions in the biopharma sector

Trump 2.0 presents opportunities and challenges for leaders of the biopharma industry, which needs effective public policy to thrive. On the latest BioCentury This Week, BioCentury Washington Editor Steve Usdin explains what those opportunities are, from modifying the Inflation Reduction Act to creating a friendlier deal-making environment under a new FTC commissioner. He also lays out the potential impact on the public policy environment, which could have repercussions on FDA, NIH, CMS and beyond. 

BioCentury’s editors then analyze how companies, academics and advocates are pushing back on claims that they should have disclosed the results of APOE4 genotype testing to Alzheimer’s trial participants. A timeline of readouts revealing the evolving picture of APOE4 and ARIA risk can be found here.

They also discuss investigations by Chinese authorities into Leon Wang, who is China president and EVP, international region of AstraZeneca plc (LSE:AZN; NASDAQ:AZN), and fellow AZ employees past and current, assessing what’s known about the allegations and whether the situation could affect other MNCs operating in the country.

Finally, Editor in Chief Simone Fishburn discusses her Editor’s Commentary on the myths that shape the perceptions those in pharma, biotech and academia have of each other. These myths, Fishburn argues, slow down, impair, or even prevent the transfer of ideas and assets that’s fundamental to the journey of a therapy from lab to patient.